Mark Pruzanski
Publications by Year
Research Areas
Drug Transport and Resistance Mechanisms, Liver Disease Diagnosis and Treatment, Cholesterol and Lipid Metabolism, Liver Diseases and Immunity, Estrogen and related hormone effects
Most-Cited Works
- → TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis(2009)1,758 cited
- → Targeting bile-acid signalling for metabolic diseases(2008)1,372 cited
- → A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis(2016)1,070 cited
- → Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease(2013)906 cited
- → Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis(2012)256 cited
- → Discovery of 6α-Ethyl-23(S)-methylcholic Acid (S-EMCA, INT-777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity(2009)250 cited
- → FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity(2017)215 cited
- → Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease(2013)215 cited
- → Protective Effects of 6-Ethyl Chenodeoxycholic Acid, a Farnesoid X Receptor Ligand, in Estrogen-Induced Cholestasis(2005)193 cited
- → Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model(2010)185 cited